Literature DB >> 20580485

Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.

David Brix1, Bruno Allolio, Wiebke Fenske, Ayman Agha, Henning Dralle, Christian Jurowich, Peter Langer, Thomas Mussack, Christoph Nies, Hubertus Riedmiller, Martin Spahn, Dirk Weismann, Stefanie Hahner, Martin Fassnacht.   

Abstract

BACKGROUND: The role of laparoscopic adrenalectomy in the treatment of patients with adrenocortical carcinoma (ACC) is controversial.
OBJECTIVE: Our aim was to compare oncologic outcome in patients with ACC who underwent either open adrenalectomy (OA) or laparoscopic adrenalectomy (LA) for localised disease. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective analysis of 152 patients with stage I-III ACC with a tumour < or =10 cm registered with the German ACC Registry. INTERVENTION: Patients were stratified into two groups according to the surgical procedure (LA or OA). For comparison, we used both a matched pairs approach by selecting for each patient from the LA group (n=35) one corresponding patient from the OA group (n=117) and multivariate analysis in all 152 patients. MEASUREMENTS: Disease-specific survival was chosen as the predefined primary end point. Secondary end points were recurrence-free survival, frequency of tumour capsule violation and postoperative peritoneal carcinomatosis, and incidence and reasons for conversion from LA to OA. RESULTS AND LIMITATIONS: LA and OA did not differ with regard to the primary end point using either the matched pairs approach (hazard ratio [HR] for death: 0.79; 95% confidence interval [CI], 0.36-1.72; p=0.55) or multivariate analysis (HR for death: 0.98; 95% CI, 0.51-1.92; p=0.92). Similarly, adjusted recurrence-free survival was not different between LA and OA (HR: 0.91; 95% CI, 0.56-1.47; p=0.69). Frequency of tumour capsule violation and peritoneal carcinomatosis were comparable between groups. In 12 of 35 patients of the LA group, surgery was converted to open surgery with no impact on the clinical outcome.
CONCLUSIONS: For localised ACC with a diameter of < or =10 cm, LA by an experienced surgeon is not inferior to OA with regard to oncologic outcome. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20580485     DOI: 10.1016/j.eururo.2010.06.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  70 in total

Review 1.  [Minimally invasive adrenal gland surgery. Transperitoneal or retroperitoneal approach?].

Authors:  M K Walz
Journal:  Chirurg       Date:  2012-06       Impact factor: 0.955

2.  Surgery: Does laparoscopic adrenalectomy have a role in suspected ACC?

Authors:  Michael J Demeure
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

Review 3.  Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature.

Authors:  Adrienne Carruth Griffin; Rachel Kelz; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

4.  Laparoscopic adrenalectomy--10-year experience at a teaching hospital.

Authors:  Sandra Sommerey; Yalda Foroghi; Costanza Chiapponi; Sebastian F Baumbach; Klaus K J Hallfeldt; Roland Ladurner; Julia K S Gallwas
Journal:  Langenbecks Arch Surg       Date:  2015-02-27       Impact factor: 3.445

Review 5.  [Surgical strategies for non-metastatic adrenocortical carcinoma].

Authors:  N Rayes; M Quinkler; T Denecke
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

6.  Adrenocortical carcinoma: effect of hospital volume on patient outcome.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Marco Boniardi; Giorgio De Toma; Luigi Antonio Marzano; Paolo Miccoli; Francesco Minni; Mario Morino; Maria Rosa Pelizzo; Andrea Pietrabissa; Andrea Renda; Andrea Valeri; Carmela De Crea; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

7.  SAGES guidelines for minimally invasive treatment of adrenal pathology.

Authors:  Dimitrios Stefanidis; Melanie Goldfarb; Kent W Kercher; William W Hope; William Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2013-09-10       Impact factor: 4.584

Review 8.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

9.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

10.  Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.

Authors:  Neda Amini; Georgios Antonios Margonis; Yuhree Kim; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-08-18       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.